Giordano Christopher Thomas 4
4 · TENAX THERAPEUTICS, INC. · Filed May 21, 2024
Insider Transaction Report
Form 4
Giordano Christopher Thomas
DirectorCEO
Transactions
- Award
Stock Option (right to buy)
2024-05-17+437→ 437 totalExercise: $3.55Exp: 2034-05-17→ Common Stock (437 underlying)
Holdings
- 157
Stock Option (right to buy)
Exercise: $3152.00Exp: 2031-07-06→ Common Stock (157 underlying) - 125
Stock Option (right to buy)
Exercise: $992.00Exp: 2032-06-09→ Common Stock (125 underlying)
Footnotes (5)
- [F1]The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of May 17, 2025, May 17, 2026, May 17, 2027, and May 17, 2028, subject to the Reporting Person's continued employment.
- [F2]These options were previously reported as covering 200,000 shares at an exercise price of $0.62 per share, but were adjusted to reflect the stock splits that occurred on January 4, 2023 and January 2, 2024.
- [F3]The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of June 9, 2023, June 9, 2024, June 9, 2025, and June 9, 2026, subject to the Reporting Person's continued employment.
- [F4]These options were previously reported as covering 250,000 shares at an exercise price of $1.97 per share, but were adjusted to reflect the stock splits that occurred on January 4, 2023 and January 2, 2024.
- [F5]The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of July 6, 2022, July 6, 2023, July 6, 2024, and July 6, 2025, subject to the Reporting Person's continued employment.